Eli Lilly and Company (LLY)vsNewGenIvf Group Limited Class A Ordinary Shares (NIVF)
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
NIVF
NewGenIvf Group Limited Class A Ordinary Shares
$1.72
-6.01%
HEALTHCARE · Cap: $1.11M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1378941% more annual revenue ($65.18B vs $4.73M). NIVF leads profitability with a 209.0% profit margin vs 31.7%. NIVF trades at a lower P/E of 0.1x. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
NIVF
Buy57
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 79 in profit
Keeps 209 of every $100 in revenue as profit
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of -349.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : NIVF
The strongest argument for NIVF centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 209.0% and operating margin at -349.1%. Revenue growth of 11.9% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : NIVF
The primary concerns for NIVF are EPS Growth, Market Cap, Operating Margin.
Key Dynamics to Monitor
LLY profiles as a growth stock while NIVF is a mature play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.50 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 57/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →NewGenIvf Group Limited Class A Ordinary Shares
HEALTHCARE · MEDICAL CARE FACILITIES · USA
NewGenIvf Group Limited (NIVF) is a leading entity in the reproductive health industry, focusing on cutting-edge fertility solutions and sophisticated in vitro fertilization (IVF) services. With a commitment to increasing success rates in assisted reproductive techniques, NIVF is strategically positioned to meet the rising global demand for fertility treatments through an established clinic network and key partnerships. As the market for fertility services continues to expand, the company is poised for significant growth, reinforcing its dedication to helping individuals and couples achieve their aspirations of parenthood.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?